Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials

24 Mar, 2021

Emalex Biosciences Raises $35 Million in Series C Preferred Stock to Advance Tourette Syndrome and Stuttering Clinical Trials
Photo by Sometimes I Snap on Unsplash

– Emalex Biopharmaceuticals raised $35m in Series C Preferred Stock funding led by Paragon Biosciences.
– The investment supports the critical work of Emalex as it pursues an effective drug therapy for people living with Tourette syndrome and childhood-onset fluency disorder (stuttering)—two conditions with high unmet needs.
– Currently, there are three Phase 2 clinical trials underway at Emalex to evaluate the efficacy and safety of its investigational first-in-class medicine, ecopipam (EBS-101).
– The round also supports organizational operations through trial completion which is expected by the end of this year.
– Emalex is one of seven companies launched by life science innovator Paragon Biosciences, founded by Chairman and CEO Jeff Aronin.

Biotechnology North America Pharmaceutical
Crunchbase icon

Content report

The following text will be sent to our editors: